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Abstract The synthesis of bile salt hydrolase has been linked to the health benefit of
Lactobacillus reuteri toward lowering blood cholesterol. The aim of this study was to
examine the growth and bile salt hydrolysis activity (BSHA) of L. reuteri NCIMB
30242 during milk fermentation with a yogurt starter. There was little growth of
L. reuteri during a 4-h co-fermentation with a yogurt culture, and an inoculation of
4.5×107 CFU.mL−1 was needed to obtain the 108 CFU.mL−1 target in the product.
Enrichment of milk with sugars, minerals, or peptone-based ingredients did not im-
prove growth of L. reuteri. Viable counts of L. reuteri above 1.5×108 CFU.mL−1
generated texture defects. Free and microencapsulated (ME) cultures were tested for
BSHA in the yogurt drinks. L. reuteri cells which grew during the 4-h lactic fermen-
tation had 40% less BSHA than L. reuteri added directly via the commercial culture.
The BSHA of free cells was apparently three times higher than in the ME culture. This
study adds data showing that the yogurt production process could affect the function-
ality of probiotic bacteria.
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1 Introduction
As scientific evidence of the benefits of probiotics continues to build, health claims
associated with fermented milks are now being recognized. Thus, the European Food
Safety Authority (EFSA) has granted a health claim on lactose digestion for yogurt
(EFSA 2010) while Switzerland’s “Office Fédéral de la Sécurité Alimentaire et des
Affaires Vétérinaires” allows claims on gastrointestinal regulation of transit time for
specific fermented milks (OSAV 2014). To our knowledge, no health claims are
currently granted for the effects of probiotics on cardiovascular diseases. Thus, prod-
ucts need to be developed and tested for the prevention of heart diseases.
A recognized link to cardiovascular health is the level of blood cholesterol. It is
considered that certain forms of cholesterol are detrimental to health and that lowering
their level in blood is desirable (Jacobson 2000). Fermented milks are recognized as
being very good matrices for functional ingredients (Shiby and Mishra 2012).
Lactobacillus reuteri NCIMB 30242 has been shown to be clinically efficacious on
reducing blood cholesterol (Jones et al. 2012a, 2012d).
However, L. reuteri has received much less attention than bifidobacteria,
Lactobacillus acidophilus, or Lactobacillus rhamnosus as potential probiotics for the
development of functional fermented milk products. Some data show limited growth in
milk and low stability during storage (Hekmat et al. 2009; Liu and Tsao 2009). One of
the reasons probiotic bacteria can influence the blood cholesterol level is by producing
bile salt hydrolase (Patel et al. 2010a, b; Jones et al. 2012a). However, there are no data
on the production of bile salt hydrolase by probiotic lactobacilli and the resulting
BSHA during milk fermentation in association with a lactic starter.
The aim of this study was therefore to examine the growth and BSHA of L. reuteri
NCIMB 30242 during milk fermentation with a yogurt starter.
2 Materials and methods
2.1 Strains
The starter culture type II from Biena (St-Hyacinthe, QC, Canada) was chosen for the
yogurt production. It is composed of Lactobacillus delbrueckii ssp. bulgaricus and
Streptococcus thermophilus strains.
L. reuteri NCIMB 30242 (LRC™) is now available at UAS Labs (Madison, WI,
USA). It was selected for this study based on its documented health effects (Jones et al.
2012a, d, 2013a and b) as well as its safety (Jones et al. 2012b, c). Although details of
the manufacturing process are proprietary to Micropharma (Montréal, QC, Canada) and
UAS Labs, the following information can be given: growth in MRS in anaerobic
conditions, centrifugation at 3300×g for 20 min, cell pellet re-suspending in a
maltodextrin/cysteine solution, and flash freezing in liquid nitrogen.
Microencapsulation in alginate and poly-L lysine gel beads was carried out as described
by Martoni et al. (2011). The resulting frozen droplets of free and microencapsulated
(ME) L. reuteri NCIMB 30242 were stored at −80 °C until used. The frozen culture of
free cells provided byMicropharma had a 4×1010 CFU.mL−1 (10.6 Log), while the ME
culture had 3.2×109 CFU.mL−1 (9.5 Log).
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2.2 Drinkable yogurt product
Commercial milk (1 and 2% milk fat) (Québon, QC, Canada) were analyzed for
protein, fat, and lactose composition by Fourier transform infrared spectroscopy
(FTIR) using a Milko Scan FT-120 unit (Foss Electric, Hillerød, Denmark). From
the data obtained by FTIR, a milk blend having 1.25% fat and 3.75% protein
was prepared by mixing 1% fat milk and 2% fat milk in a 77:23 ratio, to which
was added 12.7 g.L−1 of skimmed milk powder (Crino, Agropur, Granby, QC,
Canada), as well as 5 g.L−1 corn starch (President’s Choice, Loblaws, Toronto,
Canada) and 8.3 g.L−1 of Splenda® (Johnson & Johnson, Markham Canada).
After 30 min of hydration, the mixture was boiled and cooled to 42 °C. Unless
otherwise stated, 2 g.L−1 of pure vanilla extract (President’s Choice) was added.
The milk blend was inoculated at 1 g.L−1 with the dried starter culture, as per
recommended by the supplier. In order to obtain a product with a good texture
and cells in a similar physiological state, the inoculated milk samples were
incubated at 42 °C until a final pH of 4.5 was reached.
2.3 Inoculation level determination in co-fermentation of L. reuteri in yogurt
After inoculation with the dried starter culture, the milk mixture was separated into lots
and inoculated with frozen free-cell suspensions of L. reuteri at concentrations of 6.75,
7.05, 7.43, 7.65, 7.95, and 8.25 Log CFU.g−1. The products were incubated for 4 h at
42 °C. In some assays, the ME culture was added to finished yogurt in order to compare
BSHA of free and ME cells.
2.4 Effect of milk supplementation on the growth of L. reuteri NCIMB 30242
The milk blend standardized to 1.25% fat and 3.75% protein described above was used
for the “control,” with the exception that no Splenda or vanilla extract were added
(unless otherwise stated). The following supplements were separately added to this
control blend prior to heating: Casitone (Difco, Detroit MI, USA) at 5 g.L−1, sucrose
(LabMat, Beauport, Québec Canada) at 10 g.L−1, Splenda® at 8.3 g.L−1, Lab Lemco
meat extract (Oxoid, Nepean, Ontario, Canada) at 10 g.L−1, yeast extract (Difco) at
5 g.L−1, glucose (LabMat) at 10 g.L−1, dextrose (Fisher, Ottawa, Ontario, Canada) at
20 g.L−1, Tween at 1 g.L−1, sodium acetate (Bioshop, Burlington, Ontario, Canada) at
5 g.L−1, ammonium citrate (Bioshop) at 2 g.L−1 and potassium phosphate dibasic
(Bioshop) at 2 g.L−1, magnesium sulfate (LabMat) at 0.1 g.L−1, and manganese
sulfate (Bioshop) at 0.05 g.L−1. In some samples, 2 g.L−1 of pure vanilla extract
(President’s Choice) was then added to obtain “vanilla” and a “Splenda®-Vanilla”
media. A neutralized pasteurized yogurt (NPY) medium was produced by raising the
pH of control yogurt (described before) with KOH (5 N) from pH 4.5 to pH 7.0, in
order to obtain pH 6.6 after boiling and cooling. Medium MRS (Difco) that was used
has laboratory reference. All media were adjusted to 42 °C and, unless otherwise stated,
inoculated with the thawed free-cell suspension of L. reuteri to obtain an initial
population of 3.4×107 CFU.mL−1. After addition of the yogurt starter (1 g.L−1), the
milk-based matrices were incubated up to 6 h at 42 °C until the pH reached 4.5
(between 4 and 6 h).
Growth of Lactobacillus reuteri NCIMB 30242 175
2.5 Enumeration methods
Yogurt (10 g) was blended with 90 mL of a dissolution medium (1 g.L−1 tryptone, 8.5 g.L−1
sodium chloride, and 10 g.L−1 sodium citrate dehydrate) in a StomacherTM bag and treated
1 min in the Stomacher at “normal” speed (230 rpm). After a 10-min incubation period at
room temperature, 1 mL of the homogenate was transferred to 9 mL of 1 g.L−1 peptone
water (Difco) and homogenized 30 s at 27,000 rpm (Omni THQ). In line with the
recommendation of Champagne et al. (2011) for the enumeration of probiotics in foods,
specific steps (citrate and high-shear homogenization) were taken to allow complete
dissolution of the APA ME cultures. Serial dilutions in 1 g.L−1 peptone water were then
pour plated in MRS-T agar (tetracycline 0.9 mg.mL−1, Sigma, St. Louis, MO, USA) for
enumeration of L. reuteri (Hekmat et al. 2009) and in M17 agar for S. thermophiles counts.
The MRS-T plates were then incubated in anaerobic conditions (L. reuteri) (5% CO2, 10%
H2, and 85% N2) at 37 °C for 48 h, while M17 plates were incubated aerobically
(S. thermophilus) (ISO/IDH 2003). No selective plating for L. bulgaricus was carried out.
2.6 Enzymatic analysis
Although bile salt hydrolase is mainly produced in the cytosol and analysis can be carried
out in cell-free extracts (Liong and Shah 2005), there is activity on bacterial cell membranes
(Patel et al. 2010a, b). In this methodology, the inocula and fermentedmilk contained viable
cells. Thus, the reduction of bile salts in the testing solution could be the result of (1) bile
salt hydrolase in the yogurt resulting from cell autolysis, as well as (2) assimilation and
hydrolysis by the viable cells. Therefore, this test is technically a “bile salt hydrolysis”
analysis frommultiple bile salt hydrolase sources rather than a “bile salt hydrolase” test of a
cell-free enzyme extract. The bile salt hydrolysis activity (BSHA) was carried out as
described by Martoni et al. (2007) with modifications. Activity tests were carried out on
samples having approximately 108 CFU.mL−1. If dilution of the samples was needed, they
were made in MRS before addition to the testing medium. Various cell-free MRS or milk
controls were performed. For the analysis, 2 mL of each sample was added to 18 mL of the
testing media, which was composed of MRS supplemented with 5 mM of sodium
glycodeoxycholate (GDCA, from Sigma) and 5 mM of sodium taurodeoxycholate
(TDCA), and incubated at 37 °C with agitation at 100 rpm. Samples were analyzed at
incubation times of 15 and 30min. For each sample, 7μL of 6NHCl was added to 700μL
of sample (in Eppendorf tubes) to stop the reaction, vortexed 1 min, and centrifuged for
3 min at 10,000×g at 4 °C. An internal standard (500 μL of GCA (Sigma)) was added to
505 μL of the supernatant, vortexed 10 min, and centrifuged at 1000×g for 15 min at 4 °C.
This was followed by filtration of the supernatant (0.45 μ) and analysis by HPLC. The
HPLC analysis was carried out as described in Martoni et al. (2007).
3 Results and discussion
3.1 Growth of the cultures in milk
When inoculated alone at 1.8×107 CFU.mL−1, Lactobacillus reuteri NCIMB 30242
did not acidify milk very much (Fig. 1) and a viable count of 4.3×107 CFU.mL−1
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(7.63 Log CFU.g−1) was reached after 4 h of incubation. This limited acidification was
not due to a low inoculation rate nor to a lack of acidifying ability of this strain, since
strong growth (8.88 Log CFU.g−1) and acidification of MRS occurred following the
same inoculation level (Fig. 1). One concern was that the inocula had not been
produced in conditions that would optimize its subsequent growth in milk. Indeed,
the concentrates were produced on glucose and in a peptide-rich medium which would
not induce high β-galactosidase or proteolytic activities. Thus, cells might need to
adapt at the beginning of the 4 to 6-h yogurt production period. However, such a need
for adaptation to milk can probably be said of most probiotic cultures on the market
which are produced on MRS-like media (Champagne and Møllgaard 2008). Thus, the
culture used in this study can be considered as being “typical” for probiotics. Further
data are needed to assess the effect of the production conditions of concentrated
probiotics on their subsequent ability to grow during yogurt fermentation.
In light of this limited growth of L. reuteri in milk during the 4 to 6-h incubation
period, a series of fermentations were carried out in order to evaluate the inoculation
level (between 6.75 and 8.25 Log CFU.g−1) required to obtain at least 8.0 Log CFU.g−1
of L. reuteri in the fermented product. It was found that at least 7.65 Log CFU.g−1 was
required to achieve our goal.
Probiotics are generally only adjunct cultures, with CFUs typically at
107 CFU.mL−1. However, when CFUs attain levels above 108 CFU.mL−1 and affect
sensory properties (Champagne et al. 2005), they can “become” part of the starter
culture. As Fig. 1 shows, milk acidification was enhanced when at least 7.65 Log
CFU.g−1 of L. reuteri was inoculated in conjunction with the yogurt starter. As a
result, the time required to obtain a pH of 4.5 decreased (Fig. 2). Hekmat et al. (2009)
had not seen any effect of L. reuteri on milk acidification, when also combined with a
yogurt starter, but this is presumably because the probiotic’s viable count remained
below 106 CFU.mL−1. It was also noted in this study that the higher the L. reuteri
inoculation level was, the less was its increase in CFU (Fig. 2). This might partially be
linked to the shorter incubation time to reach pH 4.5.
Time (hours)
0 1 2 3 4
pH
4.0
4.5
5.0
5.5
6.0
6.5
7.0
L. reuteri in milk
L. reuteri in MRS
S. thermophilus in milk
S thermophilus and L. reuteri in milk
Fig. 1 Effect of the bacterial culture(s) and of the growth medium on the evolution of pH during fermentation
at 42 °C. Streptococcus thermophilus ST8 was inoculated at 4.9×107 CFU.mL−1 (7.69 Log CFU.g−1), while
Lactobacillus reuteri NCIMB 30242 was added at 4.6×107 CFU.mL−1 (7.65 Log CFU.g−1). Error bars
represent standard error of the means of three independent assays
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The viable count of S. thermophilus was affected by the L. reuteri inoculation level.
Above an inoculation of 7.95 Log CFU.g−1 of L. reuteri, there was a 40% reduction in
growth of the streptococci from 8.88 to 8.67 Log CFU.g−1. It can be hypothesized that
this was linked to the shorter fermentation time which resulted from the high
inoculation level of L. reuteri (Fig. 2), which became two times higher than
S. thermophilus. Since we were unable to selectively enumerate L. bulgaricus cells,
this study shows that the classic methodologies involving CFUs by selective media
have limits. This raises the interest of newer techniques such as PMA-qPCR
(Desfossés-Foucault et al. 2012) and flow cytometry (Geng et al. 2014), which enable
both “total” and “viable” counts of given species and even strains.
3.2 Effect of L. reuteri growth on appearance of the fermented milk
When a population above 8.17 Log CFU.g−1 of L. reuteri was attained, sensory
problems were noted. Gas bubbles and syneresis became visible. L. reuteri has a
heterofermentative metabolism, and this resulted in the production of CO2 and,
presumably, ethanol as well as acetic acid (van Niel et al. 2012).
The 8.17 Log CFU.g−1 threshold for absence of visible gas is very close to the
8.0 Log CFU.g−1 target CFU. This would be difficult to manage in a set-style yogurt
production. However, since the strategy is toward a drink, the product will be pumped
and blended. It is unknown if these operations would enable expulsion of gas and repair
the phase separation problem. Further studies are needed to establish the maximum
viable count of L. reuteri that does not result in sensory defects during storage of a
processed product.
3.3 Effect of milk supplementation or of pre-fermentation on L. reuteri growth
Attempts were made to find a supplement which could potentially promote L. reuteri
growth in milk. When compared to the milk control, none of the supplements tested
improved growth by L. reuteri (Fig. 3). Multiplication in MRS was at least 15 times
higher than in milk (Fig. 3). However, even if differences in CFUs were small, some
growth levels were found to be statistically different. CFUs in milk supplemented by a
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Fig. 2 Effect of the inoculation level of Lactobacillus reuteri NCIMB 30242 on the time required to reach a
pH of 4.5 and on the increase in CFU during the fermentation period. Error bars represent standard error of
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beef extract or by casitone were higher than those obtained in the NPY. None of the
individual ingredients significantly improved growth in milk, which suggests that low
growth might be linked to multiple limiting factors (Moroshita et al. 1981. The
supplements which had the best results were nitrogen-based (mainly casitone and beef
extract) (Fig. 3) although it could be argued that yeast extracts and beef extracts could
also provide vitamins, nucleotides, and fatty acids.
In the hope of obtaining a symbiosis (Champagne et al. 2009), assays were
conducted in which L. reuteri was added to the milk blend which had previously
experienced growth of the yogurt starter (NPY treatment). This did not occur with the
NPY treatment used in the study, which raised the possibility of antagonism between
the yogurt and L. reuteri cultures.
The possibility that the presence of oxygen was the problem, rather than a nutitional
deficiency, was also considered. However, good multiplication (Fig. 3) and activity
(Fig. 1) in MRS under the same atmospheric conditions tend to negate this hypothesis.
Further studies are required to find means of enhancing the growth of L. reuteri
NCIMB 30242 in milk and during fermentation with a yogurt culture.
3.4 Analysis of bile salt hydrolase in fermented milk
There was a strong relationship between bile salt hydrolysis activities using TDCA and
GDCA substrates. The correlation coefficient (r) between the two sets was of 0.87, and
the relationship was considered extremely significant (P value is <0.0001). Therefore,
although only the data on GDCA is presented, it must be kept in mind that the
conclusions also apply to the metabolism of TDCA.
Since the CFU target in yogurt was about 1.4×108 CFU.mL−1, BSHA calculations
were subsequently done on that cell density basis (Table 1). Attention must be given,
when reading Table 1, of the method used to calculate the BSHA readings. As data will
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show, many factors influence the apparent BSHA readings of yogurt samples which
were not diluted for analysis. Thus, when establishing the BSHA activity in yogurt
samples having L. reuteri cells, the “apparent BSHA” of probiotic-free yogurt itself
must be considered.
The free-cell concentrate provided by Micropharma used for inoculation appeared to
have almost three times more activity than the ME culture (Table 1). It must be
mentioned however that the ME culture did not dissolve in the GDCA/TDCA-MRS
medium during the 30-min assay test. Since microencapsulation in alginate lowers
mass transfer of compounds (Tanaka et al. 1984), it was not surprising that the ME
culture “apparently” had a lower specific BSHA than free cells. This is the first report
of microencapsulation potentially reducing the BSHA activity prior to dissolution. The
ME product would presumably have a higher BSHA in the duodenum since alginate
beads rapidly dissolve in that environment (Iyer et al. 2004). One must keep in mind, as
well, that ME could provide protection in the yogurt itself during storage (Champagne
et al. 2005).
Table 1 Bile salt hydrolysis activity (BSHA) (U.mL−1) of Lactobacillus reuteri NCIMB 30242 in free cell
format added to yogurt before or at the end of fermentation with different reaction times
Sample Reaction time (min) Apparent BSHA Corrected BSHA
Free cells in MRSa 0–15 35 (2) 35 (2)
15–30 23 (1) 23 (1)
0–30 29 (1) 29 (1)
ME cells in MRSa 0–15 12 (1) 12 (1)
15–30 10 (4) 10 (4)
0–30 11 (2) 11 (2)
Milk only, no starter or L. reuteri cells 0–15 68 (3) –
15–30 2 (1) –
0–30 35 (1) –
Yogurt only, no L. reuteri cells 0–15 86 (3) –
15–30 0 (0) –
0–30 43 (1) –
Yogurt with L. reuteri grown during
fermentationb
0–15 100 (6) 14 (4)
15–30 9 (2) 9 (2)
0–30 54 (4) 11 (3)
Yogurt with L. reuteri added at the
end of the fermentationb
0–15 111 (6) 25 (3)
15–30 10 (1) 10 (1)
0–30 60 (3) 18 (2)
Values presented on a basis of 1.4×108 CFU.mL−1 of L. reuteri NCIMB 30242
Values in brackets represent SEM
a The data of “corrected BSHA” are identical to those of “apparent BSHA” because there is no interference of
milk ingredients with the readings
b The data in these “corrected BSHA” column were calculated by deducting the “apparent BSHA” values of
the “yogurt only no L. reuteri cells” treatment from the “apparent BSHA” values of the “yogurt with L. reuteri
added …” treatments
C.P. Champagne et al.180
It was first examined if the reduction of the GDCAwas constant throughout the 30-
min incubation. Thus, activities were calculated after 15 and 30 min of incubation. With
MRS-grown cultures, slightly higher activities were noted in the first 15 min of
incubation, but a significant activity level was noted between 15 and 30 min
(Table 1). This suggested that GDCA reduction was linked to enzyme activity rather
than simple adsorption to the bacterial cells.
The BSHA assays on the concentrated free or ME cultures required dilution of the
concentrates in MRS broth, since cell suspensions having about 108 CFU.mL−1 work well
in this method. Thus, the reaction medium essentially contained the cells within a MRS
medium. However, the milk and fermented milk sampled contained 1.4×108 CFU.mL−1,
and the yogurt samples could not be diluted prior to addition to the GDCA/TDCA-MRS
reaction medium. It was therefore examined if the milk matrix or the yogurt product itself
could interfere with the readings. Adding cell-free milk blend to the GDCA/TDCA-MRS
produced an apparent BSHA of 35 U.mL−1 over the 30-min incubation period (Table 1).
However, the reduction of GDCA almost only occurred during the first 15 min of
incubation. This suggested that GDCA adsorbed to milk ingredients and that BSHAwas
only apparent. Since a portion of the bile molecule is hydrophobic, it was hypothesized that
the bile compoundwas adsorbed by the fat in themilk. A sample of cell-free skimmilk was
therefore tested. The result was also an apparent BSHA of 35 U.mL−1, identical to that of
the 1.25% fat milk. This suggests that fat in our yogurt mix was not responsible for the
reduction of the GDCA from themedium. It remains to be determined if binding to proteins
or whey salts (phosphates) could be responsible for the phenomenon.
When a yogurt control without L. reuteri was tested, apparent BSHAwas similarly
observed, at 43 U.mL−1 (Table 1). However, as was the case for culture-free milk, the
reduction of GDCA with the yogurt sample basically appeared in the first minutes of
incubation. No activity was noted between 15 and 30 min of incubation. This suggests
that the yogurt starter culture itself was devoid of BSHA. It has not been identified if
this slight increase in apparent BSHA, as compared to milk, was due to the acidity
brought by the yogurt and/or if the presence of the starter culture itself contributed to
GDCA adsorption. We were unable to find a method to adequately separate viable
starter bacteria from the fermented milk to test this possibility. All these data indicated
that, in order to ascertain the BSHA in fermented milk specifically linked to L. reuteri,
the blank (control) had to be a yogurt product without the probiotic strain (Table 1).
When using yogurt as a blank, the BSHA readings of 1.4×108 CFU.mL−1 of
L. reuteri directly added to yogurt was 33% lower when they were in MRS (Table 1).
3.5 Levels of bile salt hydrolysis activity in fermented yogurt
In yogurt manufacture, the probiotic culture is generally added at the beginning of
fermentation, because growth of the probiotic can occur during the incubation
(Champagne et al. 2009) and because the probiotic can subsequently be more stable
during storage (Hull et al. 1984). When the L. reuteri culture was added at the
beginning of the fermentation, the overall “corrected BSHA” (0–30 min) was almost
40% lower than when cells were added directly to the yogurt (Table 1). It is noteworthy
that the difference is mainly linked to BSHA in the first 15 min (Table 1). The lower
level of BSHA in the fermented milk is possibly due to the lack of bile salts during the
growth of L. reuteri. Indeed, in many cases, the synthesis of bile salt hydrolase is
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inducible (Patel et al. 2010a, b) and the commercial culture provided by the supplier
had been produced to have a high BSHA. Therefore, in order to have high BSHA in the
fresh yogurt, it is advisable to add cells having high BSHA directly to fermented
product. It is unknown if this inoculation approach negatively affects the subsequent
stability of L. reuteri during storage.
The ME culture can only be added to the fermented milk. Indeed, it would not remain
homogenously distributed in milk prior to fermentation and would sediment before
coagulation would occur. Data from this study suggest that inoculation of L. reuteri in
the fermented product is a good alternative for high BSHA levels. Therefore, products
withME cultures could potentially be of commercial interest. It remains to be ascertained,
however, if ME could enhance the stability of L. reuteri during storage and during
passage in the stomach. Further data on BSHA in these two conditions are needed.
4 Conclusion
This study has furthered the previously published data whereas it is possible to produce
fermented milk products with L. reuteri NCIMB 30242 having BSHA. Thus, this study
provided the following eight novel observations to the sector: (1) L. reuteri shows
limited growth during a 4-h co-fermentation with a yogurt culture; (2) within the 5.6×
106 and 1.8×108 CFU.mL−1 range, the higher the inoculation level of L. reuteri, the less
there is an increase in the probiotic population during the fermentation; (3) when the
yogurt starter is inoculated at 5×107 CFU.mL−1, an inoculation level of L. reuteri below
1×108 CFU.mL−1 does not affect the fermentation rate; (4) when the L. reuteri popu-
lation was ≥1.5×108 CFU.mL−1, texture defects (syneresis, gas bubbles) appeared in the
fermented product; (5) individual enrichment of milk with various sugars, lipids,
minerals, or peptone-based products did not improve the growth of L. reuteri over a
4-h incubation period, (6) the BSHA of free cells was apparently three times higher than
in the ME culture; (7) milk and yogurt interfere with the BSHA test, as carried out by
evaluating GDCA reduction from a MRS broth; (8) L. reuteri cells which were grown
during a 4-h fermentation has 40% less BSHA than L. reuteri added directly via the
commercial culture. When comparing the BSHA in different formats, an important
consideration is that the ME culture may be superior to free cells in protecting BSHA
during storage as well as during passage in the stomach. Further, the BSHA activity of
free cells may be related, in part, to a liberation of intracellular content.
As a result, further studies are now underway to establish the stability of free or ME
L. reuteri NCIMB 30242 cultures during storage of the fermented milk as well as
during gastric transit.
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